ULTRASTRUCTURAL FEATURES OF GAUCHER DISEASE TREATED WITH ENZYME REPLACEMENT THERAPY PRESENTING AS MESENTERIC MASS LESIONS
|
|
- Homer Carroll
- 6 years ago
- Views:
Transcription
1 Fetal and Pediatric Pathology, 25: , 2006 Copyright # Informa Healthcare ISSN: print/ online DOI: / ULTRASTRUCTURAL FEATURES OF GAUCHER DISEASE TREATED WITH ENZYME REPLACEMENT THERAPY PRESENTING AS MESENTERIC MASS LESIONS D. J. Fowler, M. A. Weber, G. Anderson, M. Malone, and N. J. Sebire & Department of Paediatric Pathology, Great Ormond Street Hospital for Children, London, United Kingdom A. Vellodi & Department of Metabolic Medicine, Great Ormond Street Hospital for Children, London, United Kingdom & The classical ultrastructural features of Gaucher disease include large numbers of intracytoplasmic, membrane-bound lysosomal inclusions containing characteristic tubular structures on an electron-lucent background, representing the periodic acid schiff (PAS) positive Gaucher cells identifiable on light microscopy. Following enzyme replacement therapy (ERT), many of the manifestations of the condition are ameliorated, but persistent mesenteric lymphadenopathy has been reported, the ultrastructural features of which previously have not been described. Two children, aged 4 and 8 years old, respectively, both presented with persistent abdominal lymphadenopathy whilst receiving ERT for Gaucher disease. Needle core biopsies were carried out, that demonstrated collections of macrophages and only scattered storage-type cells on light microscopy. PAS staining was negative in one case and only focally positive in the other. Electron microscopic examination, however, confirmed the cells represented macrophages, the cytoplasm of which contained scattered abnormal inclusions containing occasional twisted tubular structures of the type reported in classic Gaucher disease. ERT in Gaucher disease appears to reduce accumulation of the metabolic products at many sites. But for uncertain reasons, abdominal lymphadenopathy may occur containing macrophages that do not form granulomas or classic Gaucher cells on light microscopy. These probably represent incomplete clearance, incomplete=partial enzyme replacement, or possibly an unusual response to a relatively small amount of storage material. Keywords electron microscopy, enzyme replacement therapy, Gaucher disease, glucocerebrosidase deficiency, glucosylceramidase deficiency, ultrastructure Address correspondence to Dr. N. J. Sebire, Department of Pediatric Pathology, Camelia Botnar Laboratories, Great Ormond Street Hospital, London WC1N 3JH, United Kingdom. SebirN@ gosh.nhs.uk
2 242 D. J. Fowler et al. INTRODUCTION Gaucher disease (GD; glucocerebrosidase EC =glucosylceramidase EC deficiency) may manifest with a broad range of clinical features ranging from perinatal lethal presentation to asymptomatic osteopenia. Previously, the classification was wholly based on the clinical phenotype until a wide spectrum of clinical findings were recognized with broad variability in presentation. Currently, clinical subtypes are still useful in determining prognosis and management, such as the absence or presence of primary central nervous system disease: nonneurological visceral disease (type 1, GD1 (OMIM#230800) or neurological phenotypes (types 2 & 3, GD2 (OMIM#230900) & GD3 (OMIM#231000) [1]. Enzyme replacement therapy (ERT) in type 1 (GD1) has efficacy but ERT is unlikely to be useful in type 2 (GD2) because the pathogenesis represents cell death=apoptosis rather than direct effects of storage product accumulation. The perinatal lethal subtype (OMIM#608013), presenting as nonimmune hydrops inutero, and cardiovascular subtypes also are recognized, although cardiopulmonary complications are seen in all types. Currently, ERT is primarily used to treat type 1 Gaucher disease (GD1) to overcome the block in the catabolic pathway and allow clearance of accumulating storage product [2]. The native enzyme (glucocerebrosidase= glucosylceramidase) is widely distributed in a variety of mammalian tissues, including spleen and liver, and involved in the breakdown of complex glycosphingolipids (e.g., gangliosides and globoside). ERT provides exogenous recombinant enzyme preparation based on the human gene sequence but is modified to expose the carbohydrate residues for enhanced uptake by macrophages. Diagnosis of Gaucher disease is made on clinical grounds, enzyme (acid beta glucosylceramidase) activity assay (using leukocytes=fibroblasts or other nucleated cells), and morphology of characteristic storage Gaucher cells (macrophages with fibrillary cytoplasm and an eccentrically placed nucleus) in bone marrow and solid organs [3]. Although the molecular pathology of GD has been thoroughly investigated, genotype-phenotype correlations are imperfect, leading to a suspicion that epigenetic and modifying phenomena are involved in the pathogenesis. Molecular mutation analysis of GBA (glucosidase, beta acid, OMIM#606463, locus 1q21) has been used in at-risk families where the specific mutation is known and in high-risk populations where the carrier frequency of disease-causing alleles is significant. Where the mutation is known, molecular testing also can be used to accurately identify carriers. The four most common GBA mutations (N307S, L444P, 84GG, IVS2 þ 1) account for 90% of disease-causing alleles in the Ashkenazi Jewish population and 50 60% in non-jewish populations [4].
3 Ultrastructural Features of Gaucher Disease 243 FIGURE 1 Electron micrograph showing intracytoplasmic, membrane-bound lysosomal inclusions in a case of classic Gaucher disease. The typical ultrastructural features of GD include large numbers of intracytoplasmic, membrane bound lysosomal inclusions containing characteristic packed tubular structures within an electron-lucent background, representing the periodic acid schiff (PAS) positively stained Gaucher cells seen on light microscopy (Figure 1). Following ERT with imiglucerase, many of the manifestations of the condition are ameliorated, but persistent mesenteric lymphadenopathy may occur [5], the ultrastructural features of which have not been described previously. CLINICAL CASES Two children, aged 4 years (patient A) and 8 years (patient B) old, respectively, both presented with persistent significant abdominal lymphadenopathy while receiving ERT for GD. Needle core biopsies were carried out to investigate the cause of the persistent adenopathy, which in both cases demonstrated similar features. Collections of macrophages showed pale-eosinophilic cytoplasm but only scattered apparent storage-type cells on light microscopy. PAS staining was negative in one case and only focally positive in the other, and no classic Gaucher cells were identified on light microscopy (Figure 2). However, electron microscopic examination confirmed the cells to represent macrophages, the cytoplasm of which
4 244 D. J. Fowler et al. FIGURE 2 Photomicrographs of a lymph node biopsy in a patient on enzyme replacement therapy for Gaucher disease demonstrate numerous macrophages and scattered abnormal storage cells that pale cytoplasm that do not stain as classic Gaucher cells. (Top) H&E; (bottom) PAS staining. (Original magnifications 200). contained scattered abnormal membrane-bound inclusions containing scanty twisted tubular structures of the type reported in classic GD (Figure 3). Patient A originally presented aged 2 years with hepatosplenomegaly and had splenic and liver biopsies that were contributory to the diagnosis. The spleen showed infiltration of the red pulp by macrophages of classic Gaucher type and the liver showed patchy moderate fibrosis. She had a partial splenectomy=debulking surgical procedure because of the gross distention. At this time, she commenced enzyme replacement therapy. At the age
5 Ultrastructural Features of Gaucher Disease 245 FIGURE 3 Electron micrographs of storage cells from case 1 (top) and case 2 (bottom) from abdominal lymph nodes demonstrate scattered intracytoplasmic inclusions with a similar appearance to those seen in classic untreated Gaucher disease but much less abundant in number and without a clearly defined lysosomal membrane. of 4 she presented with mesenteric lymphadenopathy and the clinical issue was whether this was related to GD or an independent process such as lymphoma. However, as described above, the abdominal lymph node sampled demonstrated collections of histiocytes with foamy cytoplasm, and there was no recognizable evidence of leukemia or lymphoma. Subsequently, at age 9 the patient had persistent hepatomegaly but the spleen and kidneys had normal dimensions on imaging. She developed further abdominal and nasopharyngeal lymphadenopathy in addition to severe bone disease despite continued ERT. The total duration of ERT from start of treatment to the time of abdominal lymph node biopsy was 21 months. Patient B initially presented at the age of 2 years with hepatosplenomegaly and thrombocytopenia and bone marrow examination demonstrated numerous histiocytes with the characteristic morphological appearance of GD. Subsequently she was found to be homozygous for L444P mutation. She began ERT as part of a clinical trial, but at age 8, a routine surveillance ultrasound examination revealed enlarged abdominal lymph nodes. A biopsy was performed, that demonstrated the features described above. There was no evidence of malignancy. She has persistent abdominal
6 246 D. J. Fowler et al. lymphadenopathy to date but no other significant manifestations of tissue infiltration. The total duration of ERT from start of treatment to the time of abdominal lymph node biopsy was 7 years 1 month. DISCUSSION We report two patients developing marked mesenteric lymphadenopathy while receiving ERT for GD and describe the ultrastructural features responsible for this presentation. Although there are consensus recommendations for ERT and monitoring of children with GD, the optimal dose and frequency remains to be fully determined. The enzyme dose may be increased or decreased after initiation of treatment and during the maintenance phase based on clinical response [6, 7]. One of the current problems in ERT monitoring is the limited information regarding tissue half-life and distribution following intravenous infusion and determining whether adequate concentration of exogenous enzyme are reached in the target organs, such as bone, lung, and brain. There are limitations in assessing disease severity=improvement and rate of disease progression. Currently, the clinical course is measured by parameters such as haemopoeitic reconstitution, reduction of liver=spleen volume, and improvement in skeletal findings [8], as well as biochemical measures such as plasma tartrate resistant acid phosphatase (TRAP), liver enzymes (aspartate aminotransaminase or alanine aminotransferase), and plasma chitotriosidase. There is an enzyme dose-dependent decrease in plasma chitotriosidase activity in patients on ERT. Chitotriosidase is a macrophage-derived chitinfragmenting hydrolase that is elevated in untreated GD (up to two orders of magnitude). Several plasma markers (D-dimer, CCL18 (chemokine, CC motif ligand 18)=PARC (pulmonary and activation-regulated chemokine OMIM ), and CD163 (OMIM )) have been used in Gaucher patients as indicators of disease activity=burden that might be used in longterm monitoring and in treatment response to ERT [9 11]. However the prognostic role of these markers is still unclear. For GD1, regular intravenous infusion of imiglucerase has been shown to improve health-related quality of life, and is safe and effective in primary prevention of manifestations and reversal of hematologic and liver=spleen involvement [12, 13]. It is likely that the presence of end-stage histological changes, such as fibrosis and infarction, influence the response to ERT [4]. There may be some benefit of ERT in type 3 patients, but bone marrow transplant (BMT) or combined BMT=ERT may be of more benefit in the chronic neurological types of GD and long-term outcomes remain to be determined. In terms of gene-based therapy, the GBA gene has been introduced into hemopoietic stem cells but with only small, unsustained amounts of enzyme produced [2, 14].
7 Ultrastructural Features of Gaucher Disease 247 ERT reduces accumulation of the metabolic products at many sites, as demonstrated histologically in previous reports in which macrophages with cytoplasmic inclusions are reduced in the liver and bone marrow [15, 16]. However, for reasons that remain uncertain, abdominal lymphadenopathy due to abnormal collections of macrophages may occur, as demonstrated by the current cases. The collections of macrophages do not form histologic granulomas or collections of classic Gaucher cells on light microscopy. However, ultrastructural examination demonstrates that the cells are macrophages containing abnormal inclusions with twisted tubular structures of the type-typically seen in GD. These findings presumably represent incomplete clearance, incomplete=partial enzyme replacement at the cellular level, or possibly an unusual response to a relatively small amount of residual storage material. CONCLUSION We present two cases of pediatric Gaucher disease, both treated with ERT, who presented with persistent abdominal lymphadenopathy of unknown etiology. Although ERT prevents or reverses many of the systemic manifestations, we have demonstrated that persistent mesenteric= abdominal lymphadenopathy, due to localized collections of macrophages, with ultrastructural features of atypical Gaucher cells may occur. The reasons for the presence of these storage cells in mesenteric tissue are unclear but understanding this phenomenon may provide further insight into the efficacy of ERT at the cellular level in storage disorders. Light and electron microscopy remain important methods of assessing response to therapy in GD, which could be used in conjunction with other biological markers or as an independent morphological method for therapeutic investigation. REFERENCES 1. Beutler E, Grabowski GA. Gaucher disease. In The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, eds. New York: McGraw-Hill, Cabrera-Salazar MA, Novelli E, Barranger JA. Gene therapy for the lysosomal storage disorders. Curr Opin Mol Ther 4: , Zschocke J, Hoffman GF, eds. Vademecum Metabolicum. Manual of Metabolic Paediatrics, 2nd ed. CPI Books, Pastores GM. Gaucher disease Accessed July Lim AK, Vellodi A, McHugh K. Mesenteric mass in a young girl -an unusual site for Gaucher s disease. Pediatr Radiol 32(9): Epub July 10, Baldellou A, Andria G, Campbell PE, Charrow J, Cohen IJ, Grabowski GA, Harris CM, Kaplan P, McHugh K, Mengel E, Vellodi A. Paediatric non-neuronopathic Gaucher disease: Recommendations for treatment and monitoring. Eur J Pediatr 163:67 75, Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, Harris CM, Kaplan P, Mengel E, Pocovi M, Vellodi A. Pediatric non-neuronopathic Gaucher disease: Presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 163:58 66, 2004.
8 248 D. J. Fowler et al. 8. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki- Szymanska A. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41:4 14, Shitrit D, Rudensky B, Zimran A, Elstein D. D-dimer assay in Gaucher disease: Correlation with severity of bone and lung involvement. Am J Hematol 73: , Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, van Breemen MJ, van Meurs M, Boven LA, Laman JD, Moran MT, Cox TM, Aerts JM. Marked elevation of the chemokine CCL18=PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood 103:33 39, Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK. Plasma level of the macrophage-derived soluble CD 163 is increased and positively correlates with severity in Gaucher s disease. Eur J Haematol 72: , Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: Dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 82: , Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. Am J Med 113: , Ioannou YA, Enriquez A, Benjamin C. Gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 3: , Heukamp LC, Schroder DW, Plassman D, Homann J, Buttner R. Marked clinical and histologic improvement in a patient with type-1 Gauchers disease following long-term glucocerebroside substitution. A case report and review of current diagnosis and management. Pathol Res Pract 199: , Rudzki Z, Okon K, Machaczka M, Papla, Skotnicki AB. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease a histological study. Eur J Haematol 70: , Electronic Databases OMIM Enzyme Nomenclature:
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cerezyme) Reference Number: CP.PHAR.154 Effective Date: 02.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (VPRIV) Reference Number: CP.PHAR.163 Effective Date: 02.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Substrate Reduction Therapy Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Substrate Reduction Therapy! Prime Therapeutics will review Prior Authorization
More informationDiagnosis, monitoring and treatment of adult Gaucher patients
Diagnosis, monitoring and treatment of adult Gaucher patients Stephan vom Dahl, M.D., Professor of Medicine St. Franziskus Hospital, Köln, Germany Podčetrtek, Slovenia, April 22, 2006 Strokovni Sestanek
More informationARTICLE. The Clinical and Demographic Characteristics of Nonneuronopathic Gaucher Disease in 887 Children at Diagnosis
ARTICLE The Clinical and Demographic Characteristics of Nonneuronopathic Gaucher Disease in 887 Children at Diagnosis Paige Kaplan, MBBCh; Hans C. Andersson, MD; Katherine A. Kacena, PhD; John D. Yee,
More informationGaucher disease type I : associated morbidities and long term efficacy of enzyme replacement therapy de Fost, M.
UvA-DARE (Digital Academic Repository) Gaucher disease type I : associated morbidities and long term efficacy of enzyme replacement therapy de Fost, M. Link to publication Citation for published version
More informationLong-term treatment outcomes in Gaucher disease
REVIEW Long-term treatment outcomes in Gaucher disease AJH Joel Charrow 1,2 * and C. Ronald Scott 3 Following the treatment of the first Gaucher disease patient with enzyme replacement therapy (ERT), it
More informationImpact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher Disease Type 3
Arch. Immunol. Ther. Exp. (2015) 63:65 71 DOI 10.1007/s00005-014-0308-8 ORIGINAL ARTICLE Impact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher
More informationGaucher Disease: a multiorgan rare disease in Internal Medicine. M.Domenica Cappellini Fondazione Policlinico IRCCS University of Milan
Gaucher Disease: a multiorgan rare disease in Internal Medicine M.Domenica Cappellini Fondazione Policlinico IRCCS University of Milan XXXI Congreso Nacional de la Sociedad Espanola de Medicina Interna
More informationReport of Four Children with Gaucher Disease and Review of Literature
http:// ijp.mums.ac.ir Case Report (Pages: 2287-2293) Report of Four Children with Gaucher Disease and Review of Literature Wajiha Maan 1, *Manoochehr Karjoo 1, Mirza Beg 112 1 Department of Pediatric
More informationTREATMENTS FOR GAUCHER DISEASE
TREATMENTS FOR GAUCHER DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationIMAGING FINDINGS OF GAUCHER DISEASE IN ALL OVER THE BODY
IMAGING FINDINGS OF GAUCHER DISEASE IN ALL OVER THE BODY V. Katsaros 1, P. Lampropoulou 2, M. Mitropoulou 1, A. Nikolaou 1, C. Drossos 2 Departments of CT and MRI 1 IKA Oncology Hospital and 2 Athens General
More informationTaliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
Zimran et al. Orphanet Journal of Rare Diseases (2018) 13:36 https://doi.org/10.1186/s13023-018-0776-8 REVIEW Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with
More informationCIC Edizioni Internazionali. Clinical manifestations and management of Gaucher disease. Mini-review
Clinical manifestations and management of Gaucher disease Silvia Linari Giancarlo Castaman Center for Bleeding Disorders, Department of Heart and Vessels, Careggi University Hospital, Florence, Italy Address
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cerdelga) Reference Number: CP.PHAR.153 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationEvaluation of three biochemical markers in the monitoring of Gaucher disease
585^592 # SSIEM and Springer. Printed in the Netherlands Evaluation of three biochemical markers in the monitoring of Gaucher disease A. Vellodi 1 *, Y. Foo 2 and T. J. Cole 3 1 Metabolic Unit, 2 Chemical
More informationPOTENTIAL LINK BETWEEN GAUCHER DISEASE PATHWAYS
POTENTIAL LINK BETWEEN GAUCHER DISEASE PATHWAYS AND THOSE OF PARKINSON DISEASE Hanna Rosenbaum, MD Hematology and Bone Marrow Transplantation Rambam Medical Center and Bruce Rappaport Faculty of Medicine
More informationGoal-oriented therapy with miglustat in Gaucher disease
CURRENT MEDICAL RESEARCH AND OPINIONÕ 0300-7995 VOL. 25, NO. 1, 2009, 23 37 doi:10.1185/03007990802576518 ß 2009 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted REVIEW
More information2019 Update in Neuronopathic GD
2019 Update in Neuronopathic GD Pramod K Mistry, MD, PhD, Professor of Medicine and Pediatrics Annual NYC Meeting, Museum of the City of New York October, 29, 2017 S L I D E 1 Disclosures Received research
More informationEnzyme Replacement Therapy for Gaucher Disease: The Only Experience in Malaysia
Enzyme Replacement Therapy for Gaucher Disease: The Only Experience in Malaysia L L Chan, FRCP, H P Lin, FRCP Department of Paediatrics, University of Malaya, 50603, Lembah Pantai, Kuala Lumpur Introduction
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.241 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationChapter-6. Discussion
Chapter-6 Discussion Discussion: LSD s are disorders which collectively constitute a significant burden in the community as collectively they constitute a prevalence of 1 in 5000. The present study here
More informationOutcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
The Turkish Journal of Pediatrics 2011; 53: 499-507 Original Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response? Zeynep Arıkan-Ayyıldız
More informationThis policy addresses the coverage of Cerdelga (eliglustat) for the treatment of Gaucher disease Type 1 when appropriate criteria are met.
Subject: Cerdelga (eliglustat) Original Effective Date: 12/5/2014 Policy Number: MCP-227 Revision Date(s): 12/15/2016; 6/22/2017 Review Dates: DISCLAIMER This Molina Clinical Policy (MCP) is intended to
More informationA new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease
A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease Maja Di Rocco, 1 Fiorina Giona, 2 Francesca Carubbi, 3 Silvia Linari, 4 Fabrizio
More informationP.K. Tandon, PhD J. Alexander Cole, DSc. Use of Registries for Clinical Evaluation of Rare Diseases
Disclaimer: Presentation slides from the Rare Disease Workshop Series are posted by the Kakkis EveryLife Foundation, for educational purposes only. They are for use by drug development professionals and
More informationS2 Protein augmentation therapies for inherited disorders 1
Disease category Disorder S2 Protein augmentation therapies for inherited 1 Augmented protein 2 Source of therapeutic protein / peptide Outcome References 3 Membrane transport Coagulation Cystic fibrosis
More informationSubstrate reduction therapy as a new treatment option for patients with Gaucher disease type 1: A review of literatures
Review Article J Genet Med 2016;13(2):59-64 https://doi.org/10.5734/jgm.2016.13.2.59 ISSN 1226-1769 (Print) 2383-8442 (Online) Journal of JGM Genetic Medicine Substrate reduction therapy as a new treatment
More informationCase series. Gaucher s disease: report of 11 cases with review of literature. Open Access
Case series Open Access Gaucher s disease: report of 11 cases with review of literature Laila Essabar 1, Toufik Meskini 1,&, Najat Lamalmi 2, Said Ettair 1, Naima Erreimi 1, Nezha Mouane 1 1 FMPR, University
More informationThe following three cases of Gaucher Disease (GD) illustrate situations encountered in clinical practice; several common pitfalls are highlighted.
SUPPLEMENT Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice ABSTRACT Gaucher disease (GD) is a rare autosomal recessive disorder of glycosphingolipid metabolism resulting from deficient
More informationORIGINAL INVESTIGATION. Significant Disease Manifestations in Asymptomatic Homozygotes
Type 1 Gaucher Disease ORIGINAL INVESTIGATION Significant Disease Manifestations in Asymptomatic Homozygotes Manisha Balwani, MD, MS; Laura Fuerstman, MA; Ruth Kornreich, PhD; Lisa Edelmann, PhD; Robert
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationTYPE 1 GAUCHER DISEASE PRESENTING AS PERSISTENT THROMBOCYTOPENIA, ASSOCIATED FACTOR XI DEFICIENCY & EMERGENT MYELOMA
TYPE 1 GAUCHER DISEASE PRESENTING AS PERSISTENT THROMBOCYTOPENIA, ASSOCIATED FACTOR XI DEFICIENCY & EMERGENT MYELOMA Trish Hyland, Medical Scientist, Department of Haematology, Cork University Hospital
More informationThe role of the laboratory in diagnosing lysosomal disorders
The role of the laboratory in diagnosing lysosomal disorders Dr Guy Besley, formerly Willink Biochemical Genetics Unit, Manchester Children s Hospital, Manchester M27 4HA, UK. Lysosomal disorders What
More informationAtherosclerosis 204 (2009) Contents lists available at ScienceDirect. Atherosclerosis
Atherosclerosis 204 (2009) 267 272 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis Low HDL cholesterol levels in type I Gaucher disease
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationRecombinant Macrophage Targeted Enzyme Replacement Therapy for Gaucher Disease in India
R E S E A R C H P A P E R Recombinant Macrophage Targeted Enzyme Replacement Therapy for Gaucher Disease in India *A NAGRAL, *P MEWAWALLA, # S JAGADEESH, M KABRA, $ SR PHADKE, # IC VERMA, # RD PURI, #
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Cerezyme. This scientific discussion has been updated until 01 August 2003. For information on changes after
More informationClinical and genetic characteristics of Gaucher disease according to phenotypic subgroups
Original article http://dx.doi.org/.3345/kjp.22.55.2.4 Korean J Pediatr 22;55(2):4-53 Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups Ju-Young Lee, MD, Beom Hee
More informationA reappraisal of Gaucher disease Diagnosis and disease management algorithms
AJH Educational Material Consensus Conference A reappraisal of Gaucher disease Diagnosis and disease management algorithms Pramod K. Mistry, 1 * Maria Domenica Cappellini, 2 Elena Lukina, 3 Hayri Özsan,
More informationVelaglucerase alfa in the treatment of Gaucher disease type 1: an update
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme acid β-glucosidase.
More informationCombined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports
Amato and Patterson Journal of Medical Case Reports (2018) 12:19 DOI 10.1186/s13256-017-1541-7 CASE REPORT Open Access Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher
More informationReview of miglustat for clinical management in Gaucher disease type 1
REVIEW Review of miglustat for clinical management in Gaucher disease type 1 Can Ficicioglu The Children s Hospital of Philadelphia, Section of Biochemical Genetics Abstract: Gaucher disease is a progressive
More informationCEREZYME Genzyme. 70 mg (52 mg) (18 mg)
CEREZYME Genzyme Imiglucerase for injection 400 UNITS 200 UNITS DESCRIPTION Cerezyme (imiglucerase for injection) is an analogue of the human enzyme ß-Glucocerebrosidase, produced by recombinant DNA technology.
More informationEvaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3)
Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3) Neal J. Weinreb, University Research Foundation for
More informationEnzyme replacement therapy in type 1 Gaucher disease and a review of the literature
190 Case Report Enzyme replacement therapy in type 1 Gaucher disease and a review of the literature Tip 1 Gaucher hastalığında enzim replasman tedavisi ve literatürün gözden geçirilmesi Gökhan Kabaçam
More informationCase: The patient is a 73 year old woman with vague complaints of dyspepsia and abdominal pain. Upper endoscopy showed features of gastritis and a
Case: The patient is a 73 year old woman with vague complaints of dyspepsia and abdominal pain. Upper endoscopy showed features of gastritis and a nodular lesion in the body of the stomach. The patient
More informationIncidence. Bimodal age incidence 15-40, >55 years Childhood form (0-14) more common in developing countries M:F=1.5:1; in all subtypes except NS
Hodgkin Lymphoma Hodgkin Lymphoma 30% of all lymphomas Absolute incidence unchanged Arise in lymph node, cervical region Neoplastic tissues usually contain a small number of tumor cells Incidence Bimodal
More informationTest Utilization: Chronic Lymphocytic Leukemia
Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.
More informationPharmacy Medical Policy Alglucerase (Ceredase and Cerezyme ) for Gaucher Disease
Pharmacy Medical Policy Alglucerase (Ceredase and Cerezyme ) for Gaucher Disease Table of Contents Policy: Commercial Policy History Endnotes Policy: Medicare Information Pertaining to All Policies Forms
More informationCase 3. Ann T. Moriarty,MD
Case 3 Ann T. Moriarty,MD Case 3 59 year old male with asymptomatic cervical lymphadenopathy. These images are from a fine needle biopsy of a left cervical lymph node. Image 1 Papanicolaou Stained smear,100x.
More informationRare metabolic diseases: the miglustat experience. Fran Platt Department of Pharmacology University of Oxford
Rare metabolic diseases: the miglustat experience Fran Platt Department of Pharmacology University of Oxford The lysosome is an organelle involved in degrading and recycling macromolecules Christian de
More informationLách
Lách Lách Lách Lách Splenogonadal fusion. Splenic tissue is attached to testicular tissue. Pseudocyst (false or secondary cyst). A, Outer aspect. Pseudocyst (false or secondary cyst). B, Inner surface.
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008
MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA April 16, 2008 FACULTY COPY GOAL: Learn the appearance of normal peripheral blood elements and lymph nodes. Recognize abnormal peripheral blood
More informationPulmonary function abnormalities in type I Gaucher disease
Eur Respir J, 1996, 9, 34 345 DOI: 1.1183/931936.96.9234 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1996 European Respiratory Journal ISSN 93-1936 Pulmonary function abnormalities in
More informationEffects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
Doneda et al. Nutrition & Metabolism 2013, 10:34 REVIEW Open Access Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review Divair Doneda 1,2, Cristina
More informationNeuronopathic Gaucher Disease Day Agenda:
Neuronopathic Gaucher Disease Day Agenda: 9.15 Registration and Coffee 9.45 Conference - Introduction by Tanya Collin-Histed 9.50 Type 3 Zavesca Trial feedback session (families only) Elin Davies, Great
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationThe glucocerebrosidase locus in Gaucher's disease: molecular analysis of a lysosomal
J Med Genet 1993 30: 889-894 889 REVIEW ARTICLE Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. P K Mistry T M Cox Correspondence to Dr Mistry.
More informationOsteosclerotic Myeloma (POEMS Syndrome)
Osteosclerotic Myeloma (POEMS Syndrome) Osteosclerotic Myeloma (POEMS Syndrome) Synonyms Crow-Fukase syndrome Multicentric Castleman disease Takatsuki syndrome Acronym coined by Bardwick POEMS Scheinker,
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More informationataxia, head tremors and mild inappentence, was given palliative care
2013-5-2 Cerebellum, Spleen-Raccoon Ahmed M. Abubakar BOVINE PATHOLOGY CONTRIBUTING INSTITUTION :College of Veterinary Medicine UC Davies Signalment: Wild-caught juvenile male raccoon, ( Procyon lotor)
More informationRandomized, Controlled Trial of Miglustat in Gaucher s Disease Type 3
Randomized, Controlled Trial of Miglustat in Gaucher s Disease Type 3 Raphael Schiffmann, MD, 1 Edmond J. FitzGibbon, MD, 2 Chris Harris, PhD, 3 Catherine DeVile, MD, 4 Elin H. Davies, MSc, 4 Larry Abel,
More information-sheet 3. -Waseem Alhaj. Maha Shomaf
-sheet 3 -Basheer egbaria -Waseem Alhaj Maha Shomaf 1 P a g e Viral hepatitis have many types each type is associated with different outcomes complication, some can result in acute one,others result in
More informationSpectrum of clinical presentations
Spectrum of clinical presentations Case History A 7-day-old male patient born full-term via uncomplicated vaginal delivery was seen for multiple erythematous red-brown purpuric lesions that were present
More informationHemophagocytic Lymphohistiocytosis Secondary to T cell/histiocyte-rich Large B-cell Lymphoma
Hemophagocytic Lymphohistiocytosis Secondary to T cell/histiocyte-rich Large B-cell Lymphoma Katherine Devitt, M.D., Benjamin Chen, M.D., Ph.D., Hongbo Yu, M.D., Ph.D., Bruce Woda, M.D. 1 1 Department
More informationHAEMATOLOGICAL MALIGNANCY
HAEMATOLOGICAL MALIGNANCY Reference Compulsory reading Haematology at Glance 2 nd ed. Atul Mehta & Victor Hoffbrand Chapters: 20 to 31 Pages: 46 to 69 Pathogenesis of Haematological Malignancy Figure (a)
More informationInitiation of EnzymeReplacement Therapy for an Adult Patient with Asymptomatic T^pe 1 Gaucher's Disease
CASE REPORT Initiation of EnzymeReplacement Therapy for an Adult Patient with Asymptomatic T^pe 1 Gaucher's Disease Naoki Tanaka*-**, Hiroshi Saito*, Toshiro Ito*, Kayoko Momose*-**, Fumihiro Ishida* **,
More informationOutcome of enzyme replacement therapy in children with Gaucher disease: The Egyptian experience
The Egyptian Journal of Medical Human Genetics (2011) 12, 9 14 Ain Shams University The Egyptian Journal of Medical Human Genetics www.ejmhg.eg.net www.sciencedirect.com ORIGINAL ARTICLE Outcome of enzyme
More informationDisease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)
McGovern et al. Orphanet Journal of Rare Diseases (2017) 12:41 DOI 10.1186/s13023-017-0572-x REVIEW Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)
More informationA Lysosomal storage disease mimicking common paediatric symptoms?
A Lysosomal storage disease mimicking common paediatric symptoms? Dominique Roland 1, François Eyskens 2 1 Institut de Pathologie et de Génétique, Génétique Humaine, Centre Agréé des maladies héréditaires
More informationHODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO
HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO HODGKIN LYMPHOMA CLASSIFICATION Lukes & Butler Rye WHO-2016 Linphocytic and/or histiocytic Nodular & diffuse Nodular Sclerosis Lymphocyte
More informationDNA Polymorphism of Gaucher Disease in Iraqi Patients
DNA Polymorphism of Gaucher Disease in Iraqi Patients *Shayma`a J. Ahmed (B.Sc., M.Sc., Ph.D.Sc. in Biotechnology) ** Mohammad F. Ibraheem (M.B.CH.B., D.C.H., F.I.C.M., C.A.B.P) *** Wissam Younis Al-temimi
More informationRARE DISEASE TREATMENT RESOURCE GUIDE
TABLE OF CONTENTS Cystinosis 2 Fabry Disease 3 Gaucher Disease 4 RARE DISEASE TREATMENT RESOURCE GUIDE Cystinosis Brand Name Procysbi TM Cystagon TM Cystaran TM Generic Name Cysteamine bitartrate delayed
More informationThe lysosomal storage diseases currently number 45 and
Recommendations on Diagnosis, Treatment, and Monitoring for Gaucher Disease Ana Maria Martins, MD, PhD, Eugenia Ribeiro Valadares, MD, PhD, Gilda Porta, MD, PhD, Janice Coelho, PhD, José Semionato Filho,
More informationpatients as a potential marker for malignancy
r l a Re s e a r c h g i O in Higher levels of CD19 + in Gaucher disease patients as a potential marker for malignancy Higher levels of CD19 + in Gaucher disease Meral Dondurmacı 1, Ebru Canda 2, Melis
More informationGene Expression-Targeted Isoflavone Therapy: Facts, Questions and Further Possibilities
Gene Expression-Targeted Isoflavone Therapy: Facts, Questions and Further Possibilities Grzegorz Wegrzyn Department of Molecular Biology University of Gdansk Gdansk, Poland Lysosomal storage diseases (LSD)
More information(Plates LXVIII-LXXI)
[GANN, 54, 481-486; December, 1963] UDC 616.155.392-076.4:578.69 VIRUS-LIKE PARTICLES IN HUMAN CHLOROLEUKEMIA CELLS (Plates LXVIII-LXXI) Zensuke OTA, Shin-ya SUZUKI, and Satoru HIGASHI (Department of Internal
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationHeart disease. Other symptoms too? FABRY DISEASE IN PATIENTS WITH UNEXPLAINED HEART CONDITIONS
Heart disease Other symptoms too? FABRY DISEASE IN PATIENTS WITH UNEXPLAINED HEART CONDITIONS You have been given this brochure because your heart condition may be linked to Fabry disease, which is a rare,
More informationChapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia
Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia Introduction Cancer is a major concern in FA patients. This chapter will describe the most common types of non-head and neck solid
More informationWHAT ARE PAEDIATRIC CANCERS
WHAT ARE PAEDIATRIC CANCERS INTRODUCTION Childhood cancers are RARE 0.5% of all cancers in the West Overall risk that a child will develop cancer during first 15 years of life is 1 in 450 and 1 in 600
More informationLangerhans Cell Histiocytosis with Anterior Mediastinum, Pulmonary and Liver Involvement: CT Demonstration
Chin J Radiol 2002; 27: 191-195 191 Langerhans Cell Histiocytosis with Anterior Mediastinum, Pulmonary and Liver Involvement: CT Demonstration SIU-CHEUNG CHAN 1 MUN-CHING WONG 1 SHIU-FENG HUANG 2 WAN-CHAK
More informationORIGINAL ARTICLE CLINICOPATHOLOGICAL STUDY
CLINICOPATHOLOGICAL STUDY OF DISEASES HOMING AND INFILTRATING BONE MARROW IN CHILDREN LESS THAN 3 YEARS OF AGE M. Ramani 1, D. Ranganath 2, K. Geetha 3, Kazi Wajid Husain 4, J. Khyati Kiran 5, Puja Deshmukh
More informationSkeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
Skeletal Radiol (2014) 43:1353 1360 DOI 10.1007/s00256-014-1891-9 SCIENTIFIC ARTICLE Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat Ravi S. Kamath & Elena
More informationPathology of the Hematopoietic System. Case studies
Pathology of the Hematopoietic System Case studies Shannon Martinson, September 2015 Signalment: 9 yr-old MC cat Case Study 1 History: Cat had been anorexic and developed bleeding in the eyes Physical
More informationCASE 1. ARR 16 year old Ugandan male Senior 2 student No history of alcohol, no Tobacco
CASE 1 ARR 16 year old Ugandan male Senior 2 student No history of alcohol, no Tobacco HISTORY Index presentation to UCI, 06/09/2018 Referral Diagnosis: Burkitt s Lymphoma HISTORY 6 months of abdominal
More informationMETABOLISM OF ACYLGLYCEROLS AND SPHINGOLIPDS. Ben S. Ashok MSc.,FAGE.,PhD., Dept. of Biochemistry
METABOLISM OF ACYLGLYCEROLS AND SPHINGOLIPDS Ben S. Ashok MSc.,FAGE.,PhD., Dept. of Biochemistry STORAGE AND MEMBRANE LIPIDS STORAGE LIPIDS Mainly as triacylglycerols (triglycerides) in adipose cells Constitute
More informationPatients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes
Orenstein et al. Orphanet Journal of Rare Diseases 2014, 9:45 RESEARCH Open Access Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes
More informationNovel oral treatment of Gaucher s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
Articles Novel oral treatment of Gaucher s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis Timothy Cox, Robin Lachmann, Carla Hollak, Johannes Aerts, Sonja van Weely,
More informationAtypical cytomorphology of Gaucher cells is frequently seen in bone marrow smears from untreated patients with Gaucher disease type 1
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA Vol. 3, No., 0 pp. 6 69 ORIGINAL PAPER Atypical cytomorphology of Gaucher cells is frequently seen in bone marrow smears from untreated patients with Gaucher disease
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationGaucher disease: New developments in treatment and etiology
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2008 July 7; 14(25): 3968-3973 wjg@wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 doi:10.3748/wjg.14.3968 2008 The WJG Press. All rights
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationInternational Journal of Pharma and Bio Sciences CHROMOPHOBE VARIANT OF RENAL CELL CARCINOMA MASQUARDING AS RENAL ONCOCYTOMA ON CYTOLOGY.
Case Report Pathology International Journal of Pharma and Bio Sciences ISSN 0975-6299 CHROMOPHOBE VARIANT OF RENAL CELL CARCINOMA MASQUARDING AS RENAL ONCOCYTOMA ON CYTOLOGY. DR.MAMATHA K*, DR. ARAKERI
More informationUK National Screening Committee. Gaucher Disease Screening in Newborn. 26 November 2014
UK National Screening Committee Gaucher Disease Screening in Newborn 26 November 2014 Aim 1. This document provides background on the item addressing Gaucher disease. Current policy 2. This is the first
More informationModelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications
van Dussen et al. Orphanet Journal of Rare Diseases 24, 9:2 RESEARCH Open Access Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone
More informationGaucher disease and other storage disorders
3P SINAPOD Gaucher disease and other storage disorders Gregory A. Grabowski 1 1 Cincinnati Children s Hospital Medical Center, Cincinnati, OH In 1882, Philippe Gaucher described a 32-year-old woman with
More information